$RCUS News

Arcus Biosciences Announces New Employment Inducement Grants

How Investors May Respond To Arcus Biosciences (RCUS) $250 Million Share Sale

Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data Impresses

Arcus Biosciences, Inc. Closes Public Offering of 16,428,572 Shares of Common Stock for Net Proceeds of Approximately $269.7 million

Arcus Biosciences, Inc. Estimates $694.0 million in Cash, Cash Equivalents and Marketable Securities as of September 30, 2026

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Arcus Biosciences stock falls on public offering announcement

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Arcus Biosciences Commences Public Offering of Common Stock; Size Not Disclosed

Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day

Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

Arcus Biosciences: Encouraging Casdatifan Data, But The Hard Part Still Ahead

Arcus Reverses Course, Surging On Its Merck-Rivaling Cancer Reveal

Arcus Biosciences, Inc. (RCUS) Discusses New Data on Casdatifan for Kidney Cancer Across Multiple Lines of Therapy Transcript

Arcus Dips, But Recovers From Steep Losses, On Merck-Rivaling Cancer Data

Arcus stock tumbles 6% after unveiling casdatifan trial data

Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer